RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bicycle Therapeutics - Stock

Bicycle Therapeutics ROA 2024

Bicycle Therapeutics ROA

-0.3

Ticker

BCYC

ISIN

US0887861088

WKN

A2PKZC

In 2024, Bicycle Therapeutics's return on assets (ROA) was -0.3, a 10.54% increase from the -0.27 ROA in the previous year.

Bicycle Therapeutics Aktienanalyse

What does Bicycle Therapeutics do?

Bicycle Therapeutics PLC is a British biotechnology company specializing in the development of innovative drugs for the treatment of cancer and other diseases. The company was founded in 2009 by Sir Greg Winter, John McCafferty, and Sir Tom Blundell. They discovered a new class of molecules called Bicycles, which are small enough to penetrate the human body but large enough to selectively bind to cells and tissues and influence their biological functions. Bicycles are based on a technology called phage display, which allows for the targeted identification and isolation of molecules with specific properties. The business model of Bicycle Therapeutics revolves around using Bicycles as drug candidates for the development of new medications. The company collaborates with leading pharmaceutical and biotechnology companies to jointly develop new therapies, focusing primarily on cancer treatment due to the high demand for targeted therapies in this field. Bicycle Therapeutics has various divisions dedicated to the development of drugs for specific types of cancer. Immunoncology is one such division, which focuses on mobilizing the body's immune system to fight cancer. Another division, Targeted Payloads, concentrates on developing medications that specifically attack and destroy cancer cells. The company offers a range of products developed based on Bicycles, including therapeutic antibodies that selectively target and destroy cancer cells, as well as diagnostics for the early detection and diagnosis of cancer. One example of Bicycle Therapeutics' product is BT1718, a therapeutic antibody that specifically targets the membrane protein 5 (MP5). MP5 is expressed on the surface of various cancer cells and is therefore a promising target for cancer therapy. BT1718 has shown promising results in clinical studies involving patients with various types of cancer. Another example is BT5528, a targeted payload that targets the EphA2 receptor. EphA2 is expressed on the surface of different cancer cells and plays a crucial role in tumor progression. BT5528 is a molecule that specifically binds to EphA2 and releases a payload that attacks and destroys cancer cells. The product is currently in clinical development. Overall, Bicycle Therapeutics is a promising biotechnology company specializing in the development of innovative drugs for the treatment of cancer and other diseases. The company has a unique technology platform and collaborates with leading pharmaceutical and biotechnology companies to develop new therapies. With products like BT1718 and BT5528, Bicycle Therapeutics has already achieved promising results and remains an important player in the field of cancer therapy. Bicycle Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Bicycle Therapeutics's Return on Assets (ROA)

Bicycle Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Bicycle Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Bicycle Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Bicycle Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Bicycle Therapeutics Stock

What is the Return on Assets (ROA) of Bicycle Therapeutics this year?

The Return on Assets (ROA) of Bicycle Therapeutics is -0.3 undefined this year.

What was the ROA of Bicycle Therapeutics compared to the previous year?

The ROA of Bicycle Therapeutics has increased by 10.54% compared to the previous year.

What consequences do high ROA have for investors of Bicycle Therapeutics?

A high ROA is advantageous for investors of Bicycle Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Bicycle Therapeutics?

A low ROA can be unfavorable for investors of Bicycle Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Bicycle Therapeutics affect the company?

An increase in ROA of Bicycle Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Bicycle Therapeutics impact the company?

A reduction in the ROA of Bicycle Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Bicycle Therapeutics?

Some factors that can influence the ROA of Bicycle Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Bicycle Therapeutics important for investors?

The ROA of Bicycle Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Bicycle Therapeutics take to improve ROA?

To improve ROA, Bicycle Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Bicycle Therapeutics pay?

Over the past 12 months, Bicycle Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bicycle Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bicycle Therapeutics?

The current dividend yield of Bicycle Therapeutics is .

When does Bicycle Therapeutics pay dividends?

Bicycle Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bicycle Therapeutics?

Bicycle Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bicycle Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bicycle Therapeutics located?

Bicycle Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bicycle Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bicycle Therapeutics from 6/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/24/2024.

When did Bicycle Therapeutics pay the last dividend?

The last dividend was paid out on 6/24/2024.

What was the dividend of Bicycle Therapeutics in the year 2023?

In the year 2023, Bicycle Therapeutics distributed 0 USD as dividends.

In which currency does Bicycle Therapeutics pay out the dividend?

The dividends of Bicycle Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bicycle Therapeutics

Our stock analysis for Bicycle Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bicycle Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.